Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACCELERATE DIAGNOSTICS, INC.

(AXDX)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
1.640 USD   -1.20%
09/19ACCELERATE DIAGNOSTICS, INC.(NASDAQCM : AXDX) dropped from S&P Global BMI Index
CI
08/23ACCELERATE DIAGNOSTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/19Accelerate Diagnostics Prices Underwritten Offering of Common Stock at $2/Share; Shares Sink Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BD, Accelerate to Collaborate on Testing-Kit Distribution

08/15/2022 | 05:57am EDT

By Connor Hart


Becton, Dickinson & Co. and Accelerate Diagnostics Inc. on Monday said the companies would collaborate to bring rapid antimicrobial identification and susceptibility to more clinicians and patients worldwide.

In the collaboration, BD, a Franklin Lakes, N.J.-based medical technology company, would market and sell Accelerate Diagnostics' testing kits through its global sales network.

Accelerate, a Tucson, Ariz.-based company, offers rapid testing solutions for antibiotic resistance and susceptibility, providing results in hours as opposed to one to two days with some traditional laboratory methods, the company said.

BD would market and sell two of Accelerate's proprietary testing kits, one of which is the first test cleared by the U.S. Food and Drug Administration to deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures, the companies said.

"Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance," said Brooke Story, president of Integrated Diagnostic Solutions for BD.

Shares of Accelerate rose more than 15% in premarket trading on Monday, while shares of BD remained steady.


Write to Connor Hart at connor.hart@wsj.com


(END) Dow Jones Newswires

08-15-22 0757ET

Stocks mentioned in the article
ChangeLast1st jan.
ACCELERATE DIAGNOSTICS, INC. -1.20% 1.64 Delayed Quote.-68.58%
BECTON, DICKINSON AND COMPANY -1.38% 233.92 Delayed Quote.-4.82%
All news about ACCELERATE DIAGNOSTICS, INC.
09/19ACCELERATE DIAGNOSTICS, INC.(NASDAQC : AXDX) dropped from S&P Global BMI Index
CI
08/23ACCELERATE DIAGNOSTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/19Accelerate Diagnostics Prices Underwritten Offering of Common Stock at $2/Share; Shares..
MT
08/18Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
PR
08/18SECTOR UPDATE : Health Care Stocks Unable to Reach Positive Ground
MT
08/18SECTOR UPDATE : Health Care
MT
08/18Top Midday Decliners
MT
08/18Accelerate Diagnostics Slumps After Initiating Stock Offering
MT
08/18Top Premarket Decliners
MT
08/18Accelerate Diagnostics Initiates Stock Offering
MT
More news
Analyst Recommendations on ACCELERATE DIAGNOSTICS, INC.
More recommendations
Financials (USD)
Sales 2022 14,4 M - -
Net income 2022 -56,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,01x
Yield 2022 -
Capitalization 162 M 162 M -
Capi. / Sales 2022 11,3x
Capi. / Sales 2023 9,08x
Nbr of Employees 220
Free-Float 73,4%
Chart ACCELERATE DIAGNOSTICS, INC.
Duration : Period :
Accelerate Diagnostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERATE DIAGNOSTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,64 $
Average target price 4,00 $
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Jack Phillips President, Chief Executive Officer & Director
Steven Reichling Chief Financial & Accounting Officer
John Patience Chairman
Lawrence Mertz Chief Technology Officer
Jack W. Schuler Independent Director
Sector and Competitors